ACE2 and COVID-19: Considering together the findings that panobinostat decreases B-antigen on the KATOIII cells19, that non-O individuals have a higher risk of COVID-1918 and that higher expression of ACE2 is a risk factor for COVID-197–10, it seems plausible that panobinostat could have the potential to serve as a preventive drug against COVID-19.